RU2012108110A - Применение меланокортинов для лечения дислипидемии - Google Patents

Применение меланокортинов для лечения дислипидемии Download PDF

Info

Publication number
RU2012108110A
RU2012108110A RU2012108110/15A RU2012108110A RU2012108110A RU 2012108110 A RU2012108110 A RU 2012108110A RU 2012108110/15 A RU2012108110/15 A RU 2012108110/15A RU 2012108110 A RU2012108110 A RU 2012108110A RU 2012108110 A RU2012108110 A RU 2012108110A
Authority
RU
Russia
Prior art keywords
arg
cys
ala
trp
phe
Prior art date
Application number
RU2012108110/15A
Other languages
English (en)
Russian (ru)
Inventor
Хэзер А. ХЕЙЛЕМ
Майкл Девитт КАЛЛЕР
Original Assignee
Ипсен Фарма С.А.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ипсен Фарма С.А.С. filed Critical Ипсен Фарма С.А.С.
Publication of RU2012108110A publication Critical patent/RU2012108110A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2012108110/15A 2009-08-05 2010-07-30 Применение меланокортинов для лечения дислипидемии RU2012108110A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27348809P 2009-08-05 2009-08-05
US61/273,488 2009-08-05
PCT/US2010/043832 WO2011017209A1 (en) 2009-08-05 2010-07-30 Use of melanocortins to treat dyslipidemia

Publications (1)

Publication Number Publication Date
RU2012108110A true RU2012108110A (ru) 2013-09-10

Family

ID=43544604

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012108110/15A RU2012108110A (ru) 2009-08-05 2010-07-30 Применение меланокортинов для лечения дислипидемии

Country Status (12)

Country Link
US (2) US20120135923A1 (cg-RX-API-DMAC7.html)
EP (1) EP2461681A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013501053A (cg-RX-API-DMAC7.html)
KR (1) KR20120059520A (cg-RX-API-DMAC7.html)
CN (1) CN102548399A (cg-RX-API-DMAC7.html)
AU (1) AU2010279719A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012002445A2 (cg-RX-API-DMAC7.html)
CA (1) CA2769883A1 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN01493A (cg-RX-API-DMAC7.html)
MX (1) MX2012001513A (cg-RX-API-DMAC7.html)
RU (1) RU2012108110A (cg-RX-API-DMAC7.html)
WO (1) WO2011017209A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2453328C2 (ru) 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
US20120226018A1 (en) * 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
EP2720684B1 (en) * 2011-06-14 2019-01-16 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as the active ingredient
PT3539551T (pt) * 2011-12-29 2021-11-04 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
CA3209602A1 (en) 2013-03-15 2014-09-18 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
AU2016330773A1 (en) 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
US20210221867A1 (en) * 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
WO2006048451A1 (en) * 2004-11-04 2006-05-11 Novo Nordisk A/S Peptides for use in the treatment of obesity
CN105837661B (zh) * 2005-07-08 2024-10-15 益普生制药股份有限公司 黑皮质素受体配体
CN101528250A (zh) * 2005-07-08 2009-09-09 研究及应用科学协会股份有限公司 黑皮质素受体的配体
EP2148692B1 (en) * 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
US20100173834A1 (en) * 2007-06-15 2010-07-08 Zheng Xin Dong Cyclic peptide melanocortin receptor ligands
RU2453328C2 (ru) * 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину

Also Published As

Publication number Publication date
CA2769883A1 (en) 2011-02-10
EP2461681A4 (en) 2013-04-24
IN2012DN01493A (cg-RX-API-DMAC7.html) 2015-06-05
US20130331324A1 (en) 2013-12-12
WO2011017209A1 (en) 2011-02-10
CN102548399A (zh) 2012-07-04
EP2461681A1 (en) 2012-06-13
AU2010279719A1 (en) 2012-03-01
US20120135923A1 (en) 2012-05-31
JP2013501053A (ja) 2013-01-10
KR20120059520A (ko) 2012-06-08
BR112012002445A2 (pt) 2015-10-13
MX2012001513A (es) 2012-05-22

Similar Documents

Publication Publication Date Title
RU2012108110A (ru) Применение меланокортинов для лечения дислипидемии
RU2010122897A (ru) Применение меланокортинов для лечения чувствительности к инсулину
RU2014111472A (ru) Способ ингибирования клеточной активации, вызываемой инсулиноподобным фактором роста 1
AU2014340303B2 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
FI67539B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara peptidyl-ng-karboxyl-arginaldehyder
EA201490852A1 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP4779971B2 (ja) ヒストンデアセチラーゼ阻害剤とトポイソメラーゼｉｉ阻害剤とからなる抗腫瘍剤
US10857118B2 (en) Compositions and methods for treating intestinal hyperpermeability
EP2764871A1 (en) Methods for the prevention or treatment of heart failure
RU2011105821A (ru) Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
MX2009007830A (es) Inhibidor de rechazo cronico.
MX2008015337A (es) Metodo y compuesto para el tratamiento de estenosis valvular.
JP2013503110A5 (cg-RX-API-DMAC7.html)
Caron et al. Protein digestion and energy homeostasis: How generated peptides may impact intestinal hormones?
EP2714716A1 (en) Matriptase inhibitors and uses thereof against orthomyxoviridae infections
JP2008520682A (ja) ヒストンデアセチラーゼ阻害剤およびその使用方法
Schiffrin Endothetin: role in hypertension
WO2019246298A1 (en) Compositions and methods for the reduction or treatment of fibrosis
AU2012286594A1 (en) Modulators of protease activated receptors
RU2693478C1 (ru) Новый пептид и его применение
FI3749353T3 (fi) Nemolitsumabi keskivaikeita–vaikeita hilseilykohtia aiheuttavan atooppisen ihottuman hoidossa
JP5940542B2 (ja) 細胞導入ペプチドと皮膚導入促進剤とを組み合わせた皮膚導入システムおよび美白剤
WO2025254698A1 (en) Orally deliverable non-naturally occurring melanocortin analogs and uses thereof for modulating weight loss
WO2022265697A1 (en) Compositions for treating viral infections and methods for same
WO2025122385A1 (en) Methods and compositions for reducing scar formation and treating dermatological wounds

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20131121